Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

Theresia M. Westers, Arjan A. van de Loosdrecht, Corien Eeltink et al.|Blood|2009

Cited by 92